Is the price fair?
What TVTX's price assumes
Travere Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 5.09× revenue.
5.09
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 27.6
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 27.6
- EV / EBIToperating margin −6.8%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $5.13B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.